L&C Bio said Monday it has launched Re2O and Re2O Fine skinboosters in Mongolia following regulatory approval, as part of its expansion into Central Asia.

By introducing multiple products simultaneously, the Kosdaq-listed company aims to establish an early presence in the market, it said.

L&C Bio launched Re2O and Re2O Fine simultaneously in Mongolia after receiving regulatory approvals. (Courtesy of L&C Bio)
The launch event at Galleria Sky Ballroom in Ulaanbaatar attracted about 100 Mongolian dermatologists and plastic surgeons. The company said many attendees, including clinic directors and senior physicians, are expected to contribute to early adoption.

OAU (Ochiri Arvizikh Ur), L&C Bio’s official Mongolian distributor, organized the event and debuted Re2O and Re2O Fine. InMode, a global medical aesthetics device company, presented integrated treatments combining devices and biomaterials.

The company said the event demonstrated the effectiveness of offering a product portfolio rather than a single product.

Leading clinics in Zaisan -- known as Mongolia’s “medical street” -- have adopted Re2O, providing initial reference cases in the market. More chains, including Cinderella Clinic, have joined, supporting broader adoption through network expansion.

Key members of the Mongolian Society of Dermatology and Aesthetic Medicine, a major academic society in the country, also attended the event.

During sessions, Oh Joon-suk, head of L&C Bio’s research center, explained the scientific advantages of Re2O and Re2O Fine, supported by mechanisms and academic data. Dr. Bastsetseg U and Dr. Bulgan Kh further presented clinical perspectives on the products’ efficacy and safety.

Launching both products together is intended to address a wider range of clinical needs and improve market responsiveness, the company said. After the event, L&C Bio reported increased inquiries regarding product adoption and partnerships.

L&C Bio aims to make Mongolia a Central Asian hub, with plans to expand into Kazakhstan and Uzbekistan. The company said it will focus on building clinical references, expanding networks, and supporting market entry in additional countries.

“The launch of Re2O and Re2O Fine has strengthened our product portfolio,” an L&C Bio official said. “We will drive growth in global medical aesthetics through our ECM-based materials and device-integrated strategies, including i-JECT and LuscinX.”

Lee Ju-hee, vice president and dermatologist at L&C Bio, said, “Since launching these products in November 2024, over 300,000 procedures have confirmed their safety and efficacy. We will uphold the highest standards in tissue safety management.”

출처 : KBR(https://www.koreabiomed.com)

Published Date:2026-04-20